Arcellx climbs 19%, but the most significant Car-T presentation at ASH might not even be in oncology.

But late-breaking data raise questions about lack of a dose response.

The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.

Less than two months after a patient death CART-ddBCMA’s pivotal multiple myeloma trial is cleared to restart.